PMC:7127009 / 14764-16206 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T86","span":{"begin":61,"end":74},"obj":"Body_part"},{"id":"T87","span":{"begin":127,"end":132},"obj":"Body_part"},{"id":"T88","span":{"begin":471,"end":474},"obj":"Body_part"},{"id":"T89","span":{"begin":505,"end":520},"obj":"Body_part"},{"id":"T90","span":{"begin":515,"end":520},"obj":"Body_part"},{"id":"T91","span":{"begin":589,"end":599},"obj":"Body_part"},{"id":"T92","span":{"begin":1055,"end":1062},"obj":"Body_part"},{"id":"T93","span":{"begin":1145,"end":1153},"obj":"Body_part"}],"attributes":[{"id":"A86","pred":"fma_id","subj":"T86","obj":"http://purl.org/sig/ont/fma/fma9825"},{"id":"A87","pred":"fma_id","subj":"T87","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A88","pred":"fma_id","subj":"T88","obj":"http://purl.org/sig/ont/fma/fma67095"},{"id":"A89","pred":"fma_id","subj":"T89","obj":"http://purl.org/sig/ont/fma/fma273565"},{"id":"A90","pred":"fma_id","subj":"T90","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A91","pred":"fma_id","subj":"T91","obj":"http://purl.org/sig/ont/fma/fma63261"},{"id":"A92","pred":"fma_id","subj":"T92","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A93","pred":"fma_id","subj":"T93","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"3 The role of the checkpoints inhibitors\nThe evasion of the immune system checkpoints are often used by both malignant cancer cells and pathogens to escape immune surveillance. One of the most interesting checkpoint inhibitors is the CD200-CD200R1 system (Fig. 1). This checkpoint negatively regulates the immune response with the aim to prevent an excessive inflammatory response to different triggers [19]. Thus, it has been shown to down-modulate TLR7 (single strand RNA virus sensor) in plasmacytoid dendritic cells of a mouse model of coronavirus infection [20] and to down-modulate macrophage activation [21]. Interestingly, the inhibition of CD200-CD200R1 has positive effects on coronavirus infection [19,20,22], restoring IFN production and increasing virus clearance. Checkpoint inhibitors are currently and effectively used as therapeutic agents for a variety of cancers, but have only minimally been studied in human infectious diseases, although their function was clearly defined using the murine model of LCMV infection. A CD200-Fc fusion protein has been successfully used in experimental settings [21] and trials on inhibitory antibody targeting of CD200 has been tested for the treatment of human cancer [19], thus suggesting the intriguing possibility to use currently available checkpoint inhibitors for the treatment of CoViD-19. A trial with another checkpoint inhibitor, anti-PD1, is also ongoing in CoViD-19 patients."}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T17","span":{"begin":61,"end":74},"obj":"Body_part"}],"attributes":[{"id":"A17","pred":"uberon_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"3 The role of the checkpoints inhibitors\nThe evasion of the immune system checkpoints are often used by both malignant cancer cells and pathogens to escape immune surveillance. One of the most interesting checkpoint inhibitors is the CD200-CD200R1 system (Fig. 1). This checkpoint negatively regulates the immune response with the aim to prevent an excessive inflammatory response to different triggers [19]. Thus, it has been shown to down-modulate TLR7 (single strand RNA virus sensor) in plasmacytoid dendritic cells of a mouse model of coronavirus infection [20] and to down-modulate macrophage activation [21]. Interestingly, the inhibition of CD200-CD200R1 has positive effects on coronavirus infection [19,20,22], restoring IFN production and increasing virus clearance. Checkpoint inhibitors are currently and effectively used as therapeutic agents for a variety of cancers, but have only minimally been studied in human infectious diseases, although their function was clearly defined using the murine model of LCMV infection. A CD200-Fc fusion protein has been successfully used in experimental settings [21] and trials on inhibitory antibody targeting of CD200 has been tested for the treatment of human cancer [19], thus suggesting the intriguing possibility to use currently available checkpoint inhibitors for the treatment of CoViD-19. A trial with another checkpoint inhibitor, anti-PD1, is also ongoing in CoViD-19 patients."}

LitCovid_AGAC

{"project":"LitCovid_AGAC","denotations":[{"id":"p84668s22","span":{"begin":722,"end":731},"obj":"PosReg"},{"id":"p84668s23","span":{"begin":732,"end":746},"obj":"MPA"},{"id":"p84668s26","span":{"begin":751,"end":761},"obj":"PosReg"}],"text":"3 The role of the checkpoints inhibitors\nThe evasion of the immune system checkpoints are often used by both malignant cancer cells and pathogens to escape immune surveillance. One of the most interesting checkpoint inhibitors is the CD200-CD200R1 system (Fig. 1). This checkpoint negatively regulates the immune response with the aim to prevent an excessive inflammatory response to different triggers [19]. Thus, it has been shown to down-modulate TLR7 (single strand RNA virus sensor) in plasmacytoid dendritic cells of a mouse model of coronavirus infection [20] and to down-modulate macrophage activation [21]. Interestingly, the inhibition of CD200-CD200R1 has positive effects on coronavirus infection [19,20,22], restoring IFN production and increasing virus clearance. Checkpoint inhibitors are currently and effectively used as therapeutic agents for a variety of cancers, but have only minimally been studied in human infectious diseases, although their function was clearly defined using the murine model of LCMV infection. A CD200-Fc fusion protein has been successfully used in experimental settings [21] and trials on inhibitory antibody targeting of CD200 has been tested for the treatment of human cancer [19], thus suggesting the intriguing possibility to use currently available checkpoint inhibitors for the treatment of CoViD-19. A trial with another checkpoint inhibitor, anti-PD1, is also ongoing in CoViD-19 patients."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T119","span":{"begin":120,"end":126},"obj":"Disease"},{"id":"T120","span":{"begin":553,"end":562},"obj":"Disease"},{"id":"T121","span":{"begin":700,"end":709},"obj":"Disease"},{"id":"T122","span":{"begin":930,"end":940},"obj":"Disease"},{"id":"T123","span":{"begin":1026,"end":1035},"obj":"Disease"},{"id":"T124","span":{"begin":1216,"end":1222},"obj":"Disease"},{"id":"T125","span":{"begin":1342,"end":1350},"obj":"Disease"},{"id":"T126","span":{"begin":1424,"end":1432},"obj":"Disease"}],"attributes":[{"id":"A119","pred":"mondo_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A120","pred":"mondo_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A121","pred":"mondo_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A122","pred":"mondo_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A123","pred":"mondo_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A124","pred":"mondo_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A125","pred":"mondo_id","subj":"T125","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A126","pred":"mondo_id","subj":"T126","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"3 The role of the checkpoints inhibitors\nThe evasion of the immune system checkpoints are often used by both malignant cancer cells and pathogens to escape immune surveillance. One of the most interesting checkpoint inhibitors is the CD200-CD200R1 system (Fig. 1). This checkpoint negatively regulates the immune response with the aim to prevent an excessive inflammatory response to different triggers [19]. Thus, it has been shown to down-modulate TLR7 (single strand RNA virus sensor) in plasmacytoid dendritic cells of a mouse model of coronavirus infection [20] and to down-modulate macrophage activation [21]. Interestingly, the inhibition of CD200-CD200R1 has positive effects on coronavirus infection [19,20,22], restoring IFN production and increasing virus clearance. Checkpoint inhibitors are currently and effectively used as therapeutic agents for a variety of cancers, but have only minimally been studied in human infectious diseases, although their function was clearly defined using the murine model of LCMV infection. A CD200-Fc fusion protein has been successfully used in experimental settings [21] and trials on inhibitory antibody targeting of CD200 has been tested for the treatment of human cancer [19], thus suggesting the intriguing possibility to use currently available checkpoint inhibitors for the treatment of CoViD-19. A trial with another checkpoint inhibitor, anti-PD1, is also ongoing in CoViD-19 patients."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T149","span":{"begin":61,"end":74},"obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"T150","span":{"begin":127,"end":132},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T151","span":{"begin":332,"end":335},"obj":"http://purl.obolibrary.org/obo/PR_000001343"},{"id":"T152","span":{"begin":419,"end":422},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T153","span":{"begin":475,"end":480},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T154","span":{"begin":492,"end":520},"obj":"http://purl.obolibrary.org/obo/CL_0000784"},{"id":"T155","span":{"begin":524,"end":525},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T156","span":{"begin":526,"end":531},"obj":"http://purl.obolibrary.org/obo/CLO_0007836"},{"id":"T157","span":{"begin":600,"end":610},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T158","span":{"begin":664,"end":667},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T159","span":{"begin":762,"end":767},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T160","span":{"begin":862,"end":863},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T161","span":{"begin":924,"end":929},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T162","span":{"begin":1037,"end":1038},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T163","span":{"begin":1045,"end":1047},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T164","span":{"begin":1063,"end":1066},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T165","span":{"begin":1173,"end":1176},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T166","span":{"begin":1182,"end":1188},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T167","span":{"begin":1210,"end":1215},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T168","span":{"begin":1352,"end":1353},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"3 The role of the checkpoints inhibitors\nThe evasion of the immune system checkpoints are often used by both malignant cancer cells and pathogens to escape immune surveillance. One of the most interesting checkpoint inhibitors is the CD200-CD200R1 system (Fig. 1). This checkpoint negatively regulates the immune response with the aim to prevent an excessive inflammatory response to different triggers [19]. Thus, it has been shown to down-modulate TLR7 (single strand RNA virus sensor) in plasmacytoid dendritic cells of a mouse model of coronavirus infection [20] and to down-modulate macrophage activation [21]. Interestingly, the inhibition of CD200-CD200R1 has positive effects on coronavirus infection [19,20,22], restoring IFN production and increasing virus clearance. Checkpoint inhibitors are currently and effectively used as therapeutic agents for a variety of cancers, but have only minimally been studied in human infectious diseases, although their function was clearly defined using the murine model of LCMV infection. A CD200-Fc fusion protein has been successfully used in experimental settings [21] and trials on inhibitory antibody targeting of CD200 has been tested for the treatment of human cancer [19], thus suggesting the intriguing possibility to use currently available checkpoint inhibitors for the treatment of CoViD-19. A trial with another checkpoint inhibitor, anti-PD1, is also ongoing in CoViD-19 patients."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T79","span":{"begin":31,"end":41},"obj":"Chemical"},{"id":"T80","span":{"begin":217,"end":227},"obj":"Chemical"},{"id":"T81","span":{"begin":790,"end":800},"obj":"Chemical"},{"id":"T82","span":{"begin":1055,"end":1062},"obj":"Chemical"},{"id":"T83","span":{"begin":1310,"end":1320},"obj":"Chemical"},{"id":"T84","span":{"begin":1384,"end":1393},"obj":"Chemical"},{"id":"T85","span":{"begin":1400,"end":1403},"obj":"Chemical"}],"attributes":[{"id":"A79","pred":"chebi_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A80","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A81","pred":"chebi_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A83","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A84","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_138655"}],"text":"3 The role of the checkpoints inhibitors\nThe evasion of the immune system checkpoints are often used by both malignant cancer cells and pathogens to escape immune surveillance. One of the most interesting checkpoint inhibitors is the CD200-CD200R1 system (Fig. 1). This checkpoint negatively regulates the immune response with the aim to prevent an excessive inflammatory response to different triggers [19]. Thus, it has been shown to down-modulate TLR7 (single strand RNA virus sensor) in plasmacytoid dendritic cells of a mouse model of coronavirus infection [20] and to down-modulate macrophage activation [21]. Interestingly, the inhibition of CD200-CD200R1 has positive effects on coronavirus infection [19,20,22], restoring IFN production and increasing virus clearance. Checkpoint inhibitors are currently and effectively used as therapeutic agents for a variety of cancers, but have only minimally been studied in human infectious diseases, although their function was clearly defined using the murine model of LCMV infection. A CD200-Fc fusion protein has been successfully used in experimental settings [21] and trials on inhibitory antibody targeting of CD200 has been tested for the treatment of human cancer [19], thus suggesting the intriguing possibility to use currently available checkpoint inhibitors for the treatment of CoViD-19. A trial with another checkpoint inhibitor, anti-PD1, is also ongoing in CoViD-19 patients."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T35","span":{"begin":282,"end":322},"obj":"http://purl.obolibrary.org/obo/GO_0050777"},{"id":"T36","span":{"begin":307,"end":322},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T37","span":{"begin":360,"end":381},"obj":"http://purl.obolibrary.org/obo/GO_0006954"},{"id":"T38","span":{"begin":589,"end":610},"obj":"http://purl.obolibrary.org/obo/GO_0042116"},{"id":"T39","span":{"begin":732,"end":746},"obj":"http://purl.obolibrary.org/obo/GO_0072647"}],"text":"3 The role of the checkpoints inhibitors\nThe evasion of the immune system checkpoints are often used by both malignant cancer cells and pathogens to escape immune surveillance. One of the most interesting checkpoint inhibitors is the CD200-CD200R1 system (Fig. 1). This checkpoint negatively regulates the immune response with the aim to prevent an excessive inflammatory response to different triggers [19]. Thus, it has been shown to down-modulate TLR7 (single strand RNA virus sensor) in plasmacytoid dendritic cells of a mouse model of coronavirus infection [20] and to down-modulate macrophage activation [21]. Interestingly, the inhibition of CD200-CD200R1 has positive effects on coronavirus infection [19,20,22], restoring IFN production and increasing virus clearance. Checkpoint inhibitors are currently and effectively used as therapeutic agents for a variety of cancers, but have only minimally been studied in human infectious diseases, although their function was clearly defined using the murine model of LCMV infection. A CD200-Fc fusion protein has been successfully used in experimental settings [21] and trials on inhibitory antibody targeting of CD200 has been tested for the treatment of human cancer [19], thus suggesting the intriguing possibility to use currently available checkpoint inhibitors for the treatment of CoViD-19. A trial with another checkpoint inhibitor, anti-PD1, is also ongoing in CoViD-19 patients."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T30","span":{"begin":120,"end":126},"obj":"Phenotype"},{"id":"T31","span":{"begin":1216,"end":1222},"obj":"Phenotype"}],"attributes":[{"id":"A30","pred":"hp_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A31","pred":"hp_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"3 The role of the checkpoints inhibitors\nThe evasion of the immune system checkpoints are often used by both malignant cancer cells and pathogens to escape immune surveillance. One of the most interesting checkpoint inhibitors is the CD200-CD200R1 system (Fig. 1). This checkpoint negatively regulates the immune response with the aim to prevent an excessive inflammatory response to different triggers [19]. Thus, it has been shown to down-modulate TLR7 (single strand RNA virus sensor) in plasmacytoid dendritic cells of a mouse model of coronavirus infection [20] and to down-modulate macrophage activation [21]. Interestingly, the inhibition of CD200-CD200R1 has positive effects on coronavirus infection [19,20,22], restoring IFN production and increasing virus clearance. Checkpoint inhibitors are currently and effectively used as therapeutic agents for a variety of cancers, but have only minimally been studied in human infectious diseases, although their function was clearly defined using the murine model of LCMV infection. A CD200-Fc fusion protein has been successfully used in experimental settings [21] and trials on inhibitory antibody targeting of CD200 has been tested for the treatment of human cancer [19], thus suggesting the intriguing possibility to use currently available checkpoint inhibitors for the treatment of CoViD-19. A trial with another checkpoint inhibitor, anti-PD1, is also ongoing in CoViD-19 patients."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T85","span":{"begin":0,"end":41},"obj":"Sentence"},{"id":"T86","span":{"begin":42,"end":177},"obj":"Sentence"},{"id":"T87","span":{"begin":178,"end":265},"obj":"Sentence"},{"id":"T88","span":{"begin":266,"end":409},"obj":"Sentence"},{"id":"T89","span":{"begin":410,"end":616},"obj":"Sentence"},{"id":"T90","span":{"begin":617,"end":778},"obj":"Sentence"},{"id":"T91","span":{"begin":779,"end":1036},"obj":"Sentence"},{"id":"T92","span":{"begin":1037,"end":1351},"obj":"Sentence"},{"id":"T93","span":{"begin":1352,"end":1442},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"3 The role of the checkpoints inhibitors\nThe evasion of the immune system checkpoints are often used by both malignant cancer cells and pathogens to escape immune surveillance. One of the most interesting checkpoint inhibitors is the CD200-CD200R1 system (Fig. 1). This checkpoint negatively regulates the immune response with the aim to prevent an excessive inflammatory response to different triggers [19]. Thus, it has been shown to down-modulate TLR7 (single strand RNA virus sensor) in plasmacytoid dendritic cells of a mouse model of coronavirus infection [20] and to down-modulate macrophage activation [21]. Interestingly, the inhibition of CD200-CD200R1 has positive effects on coronavirus infection [19,20,22], restoring IFN production and increasing virus clearance. Checkpoint inhibitors are currently and effectively used as therapeutic agents for a variety of cancers, but have only minimally been studied in human infectious diseases, although their function was clearly defined using the murine model of LCMV infection. A CD200-Fc fusion protein has been successfully used in experimental settings [21] and trials on inhibitory antibody targeting of CD200 has been tested for the treatment of human cancer [19], thus suggesting the intriguing possibility to use currently available checkpoint inhibitors for the treatment of CoViD-19. A trial with another checkpoint inhibitor, anti-PD1, is also ongoing in CoViD-19 patients."}

LitCovid-PMC-OGER-BB

2_test

{"project":"2_test","denotations":[{"id":"32253068-24388216-55639831","span":{"begin":404,"end":406},"obj":"24388216"},{"id":"32253068-24388216-55639832","span":{"begin":710,"end":712},"obj":"24388216"},{"id":"32253068-24388216-55639833","span":{"begin":1223,"end":1225},"obj":"24388216"}],"text":"3 The role of the checkpoints inhibitors\nThe evasion of the immune system checkpoints are often used by both malignant cancer cells and pathogens to escape immune surveillance. One of the most interesting checkpoint inhibitors is the CD200-CD200R1 system (Fig. 1). This checkpoint negatively regulates the immune response with the aim to prevent an excessive inflammatory response to different triggers [19]. Thus, it has been shown to down-modulate TLR7 (single strand RNA virus sensor) in plasmacytoid dendritic cells of a mouse model of coronavirus infection [20] and to down-modulate macrophage activation [21]. Interestingly, the inhibition of CD200-CD200R1 has positive effects on coronavirus infection [19,20,22], restoring IFN production and increasing virus clearance. Checkpoint inhibitors are currently and effectively used as therapeutic agents for a variety of cancers, but have only minimally been studied in human infectious diseases, although their function was clearly defined using the murine model of LCMV infection. A CD200-Fc fusion protein has been successfully used in experimental settings [21] and trials on inhibitory antibody targeting of CD200 has been tested for the treatment of human cancer [19], thus suggesting the intriguing possibility to use currently available checkpoint inhibitors for the treatment of CoViD-19. A trial with another checkpoint inhibitor, anti-PD1, is also ongoing in CoViD-19 patients."}

PMC:7127009 / 14764-16206 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7127009 / 14764-16206 JSON TXT